A multiple-dose, open-labelled, randomized, two period crossover human volunteer study
was performed (i) to describe the pharmacokinetic profile and safety profile of piperacillin …

Six isolates each of Enterococcus faecium, Staphylococcus aureus, Staphylococcus
epidermidis, Streptococcus pyogenes, Stenotrophomonas maltophilia, Pseudomonas …

The pharmacokinetic properties of piperacillin/tazobactam are summarized. The data on
piperacillin show that the behaviour of this well established agent is the same when given in …

Background: Although intermittent bolus dosing is currently the standard of practice for many
antimicrobial agents, beta-lactams exhibit time-dependent bacterial killing. Maximizing the …

The safety of piperacillin/tazobactam was investigated in Phase I and Phase III clinical
studies. In 22 Phase I pharmacokinetic studies, 242 healthy subjects and 232 patients were …

The primary objectives of this analysis were to determine which pharmacokinetic model
most accurately describes the elimination pathways for piperacillin in the presence of …

With increasing use of once-daily aminoglycoside dosing and renewed interest in
continuous infusions of p-lactam agents, there is a need to study the interaction between …

Polymicrobial infections are characterized by the presence of micro-organisms from more
than one group of bacteria. Empirical treatment of polymicrobial infections requires an agent …

Importance of the field: Piperacillin-tazobactam is a frequently prescribed intravenous
antibiotic for moderate to severe infections used in hospital settings because of its broad …

Piperacillin/tazobactam is the most recently approved combination of a β-lactam agent with
an inhibitor of bacterial β-lactamases. It has a broader spectrum than do preceding inhibitor …